Middle East and Africa Animal and Human Vaccines Market, By Type (Human and Animal), End User (Hospitals, Clinics, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others) - Industry Trends and Forecast to 2031.
Middle East and Africa Animal and Human Vaccines Market Analysis and Insights
The prevalence of infectious diseases is increasing worldwide and this has been seen that flu and bacterial infectious diseases are surging at a rapid rate, which is boosting the market growth. The mild side-effects which are redness, soreness, or swelling at the injection site can include allergic reactions, and responses are extremely uncommon and it is expected to challenge the market growth.
Data Bridge Market Research analyses that the Middle East and Africa animal and human vaccines market is expected to reach USD 5,358,452.80 thousand by 2031 from USD 3,480,103.50 thousand in 2023, growing with a CAGR of 5.6% in the forecast period of 2024 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Type (Human and Animal), End User (Hospitals, Clinics, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others)
|
|
Countries Covered
|
Saudi Arabia, Egypt, U.A.E., Israel, Iran, Iraq, Oman, Kuwait, Qatar, Bahrain, Yemen, Jordan, Lebanon, Palestine, Rest of Middle East, South Africa, Nigeria, Ethiopia, Tanzania, Kenya, Algeria, Ghana, Mozambique, Uganda, Democratic Republic of Congo, Sudan, Morocco, Angola, Madagascar, Malawi, Zambia, Ivory Coast, Cameroon, Zimbabwe, Libya, Chad, Botswana, Namibia, Lesotho, Mauritius, Eswatini, Comoros, Seychelles, and Rest of Africa
|
|
Market Players Covered
|
GSK plc., Merck & Co., Inc., Sanofi, Boehringer Ingelheim International GmbH., Ceva, ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC (PTY) LTD, M.C.I Santé Animale, Biogénesis Bagó, and HESTER BIOSCIENCES LIMITED among others
|
Market Definition
Vaccines are the product that stimulates the individual immune system to induce immunity against a particular disease. Vaccines work on the principle of memory and recognition. When weakened or killed microbes are injected into a body, these microbes cause B cells which are memory cells of the immune system to recognize the pathogen, and in the future, if the same pathogen attacks the body, it works against those. Vaccines have been discovered for several kinds of infectious diseases prevailing around including pneumococcal disease, measles, mumps, rubella, hepatitis, influenza, typhoid, varicella, and rabies among others.
Middle East and Africa Animal and Human Vaccines Market Dynamics
This section deals with understanding the market drivers, opportunities, challenges, and restraints. All of this is discussed in detail below:
Drivers
- Growing Immunization Programs and Campaigns
Implementing a robust immunization program in Middle Eastern and African countries is vital for enhancing public health and preventing the spread of infectious diseases. To ensure the success of such initiatives, it is crucial to undertake comprehensive awareness campaigns. Immunization programs and campaigns are increasing worldwide because of the increasing number of chronic diseases. There is an urgent need to increase awareness regarding vaccination that can be achieved by launching several campaigns and programs, as hepatitis, diphtheria, pertussis, and polio, among other infectious diseases, are prevailing in the environment. This has been reported that the number of immunization programs is increasing with an increase in infectious diseases. Along with this, immunization coverage is also increasing worldwide intending to fight against debilitating diseases.
- Growing Prevalence of Chronic Conditions
The prevalence of infectious diseases is increasing worldwide and this has been seen that flu and bacterial infectious diseases are surging at a rapid rate. This increasing rate of infectious diseases has created the need for disease prevention which can be prevented by vaccination or immunization. There is an urgent need for mass vaccination, as diseases are increasing at a significant rate. Mass vaccinations require a large amount of vaccine disease, hence expected to provide the market with lucrative growth. The prevalence of growing chronic diseases worldwide has significantly heightened the demand for vaccines, thereby expanding the vaccine market. In response to this escalating health challenge, there is a growing recognition of the preventive role that vaccines can play in reducing the incidence and severity of various chronic illnesses.
Opportunity
- Strategic Initiation and Decision taken by the Market Players
Various strategic initiatives are adopted by market players in the vaccine market which involve expansion, collaboration, and acquisition among others. These initiatives allow them to increase the company's product portfolio leading to market expansion and hence enhancing the product demand among customers which ultimately allows the market players to earn maximum revenue. One critical aspect involves continuous investment in research and development to innovate and introduce new vaccines that address emerging health threats. Collaborations with research institutions, government agencies, and Middle East and Africa health organizations help in leveraging collective expertise and resources.
These strategic initiatives are taken by top market players aimed at enhancing business operations and earning more profitability in the market as the demand for effective and novel vaccines is increasing worldwide.
Restraints/Challenges
- Unavailability of Registered Vaccines in the Market
The strict regulatory approvals and time-consuming development procedures for the vaccines are some of the factors that are responsible for the unavailability of registered vaccines. The unavailability of a registered vaccine can have significant implications for public health, creating challenges in disease prevention and control. When a vaccine is not available, it may lead to increased vulnerability to infectious diseases, potential outbreaks, and a higher risk of severe health consequences for the population. Addressing the unavailability of a registered vaccine involves a combination of efforts from regulatory bodies, pharmaceutical companies, and healthcare systems. The regulatory authorities find difficulties in the assessment, licensure, control, and surveillance of vaccines. The world supply of vaccines is delayed due to these regulations.
- Harmful Side Effects Caused by Vaccination
The vaccine is a medical product and helps in preventing different diseases. But sometimes the side-effects arise due to the use of the vaccines. Some of them are the mild side-effects which are redness, soreness, or swelling at the injection site. The vast majority of vaccine side effects are mild and temporary, and the benefits of vaccination in preventing serious illnesses far outweigh the risks. These can include allergic reactions, though severe allergic responses are extremely uncommon. In addition, vaccines, such as any medical intervention, can have rare but serious side effects such as Guillain-Barre Syndrome (GBS) or thrombosis. However, the adverse side effects of the vaccines are rare but are life-threatening.
Recent Developments
- In January 2023, Senvelgo, the recent innovation from Boehringer Ingelheim, has secured the prestigious Animal Health Best New Product for Companion Animals award. This accolade recognizes Senvelgo for its remarkable contribution to simplifying and enhancing the treatment of diabetic cats. Boehringer Ingelheim's commitment to innovation is evident in Senvelgo, offering a solution that is not only simple and safe but also highly convenient for both feline patients and their caregivers
- In 2023, Merck & Co., Inc. received approval from the U.S. Food and Drug Administration (FDA) for KEYTRUDA, its anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for treating patients with FIGO 2014 Stage III-IVA cervical cancer. This approval is based on positive results from the Phase 3 KEYNOTE-A18 trial, where KEYTRUDA combined with CRT showed a 41% reduction in the risk of disease progression or death compared to a placebo plus CRT. The median progression-free survival (PFS) was not reached in either group. This marks the third indication for KEYTRUDA in cervical cancer, emphasizing its effectiveness, and it is the 39th overall indication for KEYTRUDA in the United States. This milestone underscores Merck's commitment to advancing treatment options for patients with various types of cancer
- In July 2023, Biogenesis Bago announced BIOAFTOGEN under the Food and Agriculture Organization of the United Nations (FAO). This marks a historic moment as BIOAFTOGEN becomes the first FMD vaccine to receive such prequalification. This achievement enhances the company´s position as a global leader in FMD prevention and reinforces its commitment to collaboration with leading technical and scientific organizations, contributing to food safety and animal health status worldwide
- In November 2020, GSK plc. along with Medicines for Malaria Venture presented positive data (TEACH study) of tafenoquine used for the treatment of Plasmodium vivax malaria in children and adolescents. During the four months of examination, 95% of study’s 60 subjects did not show signs of Plasmodium vivax malaria. The results were presented through a virtual annual meeting of the American Society of Tropical Medicine & hygiene 2020. This has helped the company to move forward on the product for the treatment of malaria and to provide evidence of their product
- In November 2020, Sanofi received approval from the European Commission for Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza disease in adults aged 18 years or older. This approval helped the company to advance its product portfolio involving vaccines and to strengthen its roots in the European vaccine market
Middle East and Africa Animal and Human Vaccines Market Scope
The Middle East and Africa animal and human vaccines market is categorized into three notable segments based on type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Human
- Animal
On the basis of type, the Middle East and Africa animal and human vaccines market is segmented into human and animal.
End User
- Hospitals
- Clinics
- Others
On the basis of end user, the Middle East and Africa animal and human vaccines market is segmented into hospitals, clinics, and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Others
On the basis of distrution channel, the Middle East and Africa animal and human vaccines market is segmented into direct tender, retail sales, and others.
Middle East and Africa Animal and Human Vaccines Market Regional Analysis/Insights
The Middle East and Africa animal and vaccines market is categorized into three notable segments into type, end user, and distribution channel.
The countries covered in this market report are Saudi Arabia, Egypt, U.A.E., Israel, Iran, Iraq, Oman, Kuwait, Qatar, Bahrain, Yemen, Jordan, Lebanon, Palestine, rest of Middle East, South Africa, Nigeria, Ethiopia, Tanzania, Kenya, Algeria, Ghana, Mozambique, Uganda, Democratic Republic of Congo, Sudan, Morocco, Angola, Madagascar, Malawi, Zambia, Ivory Coast, Cameroon, Zimbabwe, Libya, Chad, Botswana, Namibia, Lesotho, Mauritius, Eswatini, Comoros, Seychelles, and rest of Africa.
South Africa is expected to dominate the Africa animal and vaccines market due to increasing government support and funding in the country. Saudi Arabia is expected to dominate the Middle East animal and vaccines market due to growing immunization programs and campaigns.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Middle East and Africa Animal and Human Vaccines Market Competitive Landscape and Share Analysis
Middle East and Africa animal and human vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the Middle East and Africa animal and human vaccines market.
Some of the major players operating in the Middle East and Africa animal and human vaccines market are GSK plc., Merck & Co., Inc., Sanofi, Boehringer Ingelheim International GmbH., Ceva, ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC (PTY) LTD, M.C.I Santé Animale, Biogénesis Bagó, and HESTER BIOSCIENCES LIMITED among others.
SKU-